UnknownNCT04297891
Phenotypes, Biomarkers and Pathophysiology in Spastic Ataxias
Studying Spastic ataxia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dr. Rebecca Schule
- Principal Investigator
- Rebecca Schüle, PD Dr.University Hospital Tübingen
- Intervention
- Clinical rating scale to measure Ataxia disease severity and progression(other)
- Enrollment
- 250 enrolled
- Eligibility
- All sexes
- Timeline
- 2020 – 2025
Study locations (9)
- Montreal Neurological Institute of McGill University, Department of Neurology and Neurosurgery and Human Genetics, Montreal, Quebec, Canada
- Université de Sherbrooke, Saguenay, Quebec, Canada
- Département d'information médicale (DIM); Département de Biostatistique, Santn 3emé Publique et Information Médicale (BIOSPIM)- Bâtiment Mazarie étage; Hôpitaux Universitaires Pitié Salpêtrière, Paris, France
- Center for Neurology & Hertie-Institute for Clinical Brain Research, Dept. for Neurodegenerative Diseases, Tübingen, Baden-Wurttemberg, Germany
- University Hospital Essen (AöR), Essen, Germany
- IRCCS Fondazione Stella Maris, Pisa, Italy
- Radboud University Medical Center; Department of Neurology & Donders Institute for Brain, Cognition, and Behaviour, Nijmegen, Netherlands
- Koç Univ. Hospital, KUTTAMNDAL, Istanbul, Turkey (Türkiye)
- Department of Clinical Neurosciences, University of Cambridge; John Van Geest Cambridge Centre for Brain Repair, Cambridge, United Kingdom
Collaborators
German Center for Neurodegenerative Diseases (DZNE) · German Research Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04297891 on ClinicalTrials.gov